Susquehanna International Group’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.5M Sell
467,800
-310,500
-40% -$9.25M ﹤0.01% 2527
2025
Q4
$23.2M Sell
778,300
-30,200
-4% -$986K ﹤0.01% 2050
2025
Q3
$29.2M Buy
808,500
+183,300
+29% +$6.04M ﹤0.01% 1815
2025
Q2
$22.5M Sell
625,200
-32,800
-5% -$1.22M ﹤0.01% 1884
2025
Q1
$25.9M Sell
658,000
-616,200
-48% -$20.7M ﹤0.01% 1511
2024
Q4
$38.4M Buy
1,274,200
+435,800
+52% +$12.5M 0.01% 1314
2024
Q3
$19.6M Buy
838,400
+127,100
+18% +$2.78M ﹤0.01% 1853
2024
Q2
$12.7M Sell
711,300
-166,300
-19% -$2.65M ﹤0.01% 2204
2024
Q1
$13.3M Sell
877,600
-323,400
-27% -$5.15M ﹤0.01% 2235
2023
Q4
$20.5M Buy
1,201,000
+180,000
+18% +$2.09M ﹤0.01% 1786
2023
Q3
$8.54M Buy
1,021,000
+59,900
+6% +$835K ﹤0.01% 2763
2023
Q2
$23.9M Buy
961,100
+333,200
+53% +$8.61M ﹤0.01% 1559
2023
Q1
$9.44M Sell
627,900
-240,200
-28% -$3.65M ﹤0.01% 2535
2022
Q4
$10.3M Buy
868,100
+454,500
+110% +$3.3M ﹤0.01% 2237
2022
Q3
$2.45M Buy
413,600
+59,900
+17% +$393K ﹤0.01% 4515
2022
Q2
$1.5M Sell
353,700
-54,000
-13% -$337K ﹤0.01% 5533
2022
Q1
$3.88M Buy
407,700
+48,300
+13% +$559K ﹤0.01% 4125
2021
Q4
$6.83M Buy
359,400
+45,900
+15% +$1.19M ﹤0.01% 3239
2021
Q3
$10.4M Buy
313,500
+41,500
+15% +$1.28M ﹤0.01% 2803
2021
Q2
$10.6M Sell
272,000
-81,200
-23% -$3.19M ﹤0.01% 2845
2021
Q1
$17M Sell
353,200
-28,100
-7% -$1.35M ﹤0.01% 2074
2020
Q4
$19.8M Buy
381,300
+23,400
+7% +$791K ﹤0.01% 1746
2020
Q3
$9.58M Buy
357,900
+118,900
+50% +$2.74M ﹤0.01% 2239
2020
Q2
$4.66M Buy
239,000
+65,900
+38% +$1.06M ﹤0.01% 3101
2020
Q1
$1.7M Sell
173,100
-44,100
-20% -$557K ﹤0.01% 4262
2019
Q4
$2.41M Buy
217,200
+132,300
+156% +$1.01M ﹤0.01% 4019
2019
Q3
$477K Sell
84,900
-76,200
-47% -$531K ﹤0.01% 7407
2019
Q2
$1.39M Sell
161,100
-82,800
-34% -$626K ﹤0.01% 4933
2019
Q1
$1.96M Buy
243,900
+190,200
+354% +$1.03M ﹤0.01% 3776
2018
Q4
$220K Sell
53,700
-213,500
-80% -$1.06M ﹤0.01% 7567
2018
Q3
$1.5M Buy
267,200
+39,600
+17% +$452K ﹤0.01% 4487
2018
Q2
$2.99M Sell
227,600
-69,900
-23% -$961K ﹤0.01% 3384
2018
Q1
$4.22M Buy
297,500
+96,000
+48% +$1.23M ﹤0.01% 2753
2017
Q4
$1.65M Buy
201,500
+6,200
+3% +$54.2K ﹤0.01% 4263
2017
Q3
$2.31M Buy
195,300
+17,600
+10% +$200K ﹤0.01% 3643
2017
Q2
$1.79M Buy
177,700
+59,700
+51% +$668K ﹤0.01% 4112
2017
Q1
$1.38M Buy
118,000
+69,700
+144% +$500K ﹤0.01% 4459
2016
Q4
$225K Buy
48,300
+13,900
+40% +$81.5K ﹤0.01% 8484
2016
Q3
$266K Sell
34,400
-1,100
-3% -$7.08K ﹤0.01% 7129
2016
Q2
$215K Sell
35,500
-54,500
-61% -$443K ﹤0.01% 7495
2016
Q1
$767K Buy
90,000
+22,400
+33% +$196K ﹤0.01% 5614
2015
Q4
$806K Buy
67,600
+30,500
+82% +$385K ﹤0.01% 5848
2015
Q3
$374K Sell
37,100
-91,500
-71% -$1.36M ﹤0.01% 7653
2015
Q2
$2.13M Buy
128,600
+6,500
+5% +$103K ﹤0.01% 4583
2015
Q1
$1.89M Buy
122,100
+92,200
+308% +$1.4M ﹤0.01% 4422
2014
Q4
$474K Sell
29,900
-44,300
-60% -$577K ﹤0.01% 7309
2014
Q3
$792K Sell
74,200
-6,200
-8% -$57.5K ﹤0.01% 6385
2014
Q2
$755K Buy
80,400
+61,300
+321% +$392K ﹤0.01% 6650
2014
Q1
$132K Buy
19,100
+5,600
+41% +$33.1K ﹤0.01% 8476
2013
Q4
$53K Buy
+13,500
New +$54.5K ﹤0.01% 8786

Other funds holding TGTX

Susquehanna International Group's TGTX Position: Q1 2026 in Review

Susquehanna International Group reduced its TG Therapeutics (TGTX) stake by 39% in Q1 2026, selling an estimated $10.2M and leaving 544,720 shares worth $18.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

Susquehanna International Group first reported a position in TGTX in Q2 2013 and has held it in 49 quarters since. The position peaked at $55.7M in Q2 2021. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Susquehanna International Group held 544,720 shares of TG Therapeutics worth $18.1M as of Q1 2026.
  • Susquehanna International Group sold 342,731 TG Therapeutics shares in Q1 2026, an estimated $10.2M.
  • TG Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2356 holding.
  • Susquehanna International Group first reported a position in TG Therapeutics in Q2 2013 and has held it in 49 quarters since.
  • Susquehanna International Group's TG Therapeutics position peaked at $55.7M in Q2 2021.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.